DEERFIELD MANAGEMENT COMPANY, L.P.
An institutional investment manager in New York, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 1009258.
- Reported value$9.59bn
- Positions82
Holdings: 82 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Nuvalent Inc | COM | 670703107 | 2,130 | 22.2% | 17,248,450 | Unchanged | |
| Brookdale SR Living Inc | NOTE 3.500%10/1 | 112463AF1 | 586 | 6.1% | $306,885,000 principal | Unchanged | |
| Revolution Medicines IncRVMD | COM | 76155X100 | 448 | 4.7% | 2,392,000 | Added+95,000 | |
| Praxis Precision Medicines IPRAX | COM NEW | 74006W207 | 323 | 3.4% | 963,351 | Unchanged | |
| Viatris IncVTRS | COM | 92556V106 | 321 | 3.3% | 20,206,170 | Unchanged | |
| Centene Corp DelCNC | COM | 15135B101 | 315 | 3.3% | 4,901,000 | Reduced−1,016,091 | |
| Revolution Medicines Inc | NOTE 0.500% 5/0 | 76155XAA8 | 252 | 2.6% | $200,000,000 principal | New+200,000,000 | |
| United Therapeutics Corp DelUTHR | COM | 91307C102 | 248 | 2.6% | 457,000 | Unchanged | |
| Arrowhead Pharmaceuticals in | NOTE 1/1 | 04280AAC4 | 241 | 2.5% | $200,000,000 principal | Unchanged | |
| Legend Biotech CorpLEGN | SPONSORED ADS | 52490G102 | 235 | 2.5% | 8,137,638 | Added+450,000 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 194 | 2.0% | 5,006,104 | Reduced−4,037,799 | |
| Genmab A/SGMAB | SPONSORED ADS | 372303206 | 189 | 2.0% | 6,865,000 | Added+4,403,000 | |
| Brookdale SR Living IncBKD | COM | 112463104 | 187 | 2.0% | 11,637,032 | Unchanged | |
| Vera Therapeutics IncVERA | CL A | 92337R101 | 168 | 1.8% | 3,916,400 | Added+194,300 | |
| Ionis Pharmaceuticals IncIONS | COM | 462222100 | 157 | 1.6% | 1,979,669 | Unchanged | |
| Celcuity IncCELC | COM | 15102K100 | 152 | 1.6% | 1,451,014 | Reduced−262,986 | |
| Biocryst Pharmaceuticals IncBCRX | COM | 09058V103 | 151 | 1.6% | 15,096,403 | Added+58,403 | |
| Newamsterdam Pharma Company | ORDINARY SHARES | N62509109 | 145 | 1.5% | 4,264,789 | Unchanged | |
| Acadia Healthcare Company inACHC | COM | 00404A109 | 133 | 1.4% | 4,520,000 | Unchanged | |
| Tango Therapeutics IncTNGX | COM | 87583X109 | 131 | 1.4% | 4,190,611 | Added+43,798 | |
| Adapthealth CorpAHCO | COMMON STOCK | 00653Q102 | 120 | 1.2% | 11,477,730 | Unchanged | |
| Pharvaris N V | COM | N69605108 | 117 | 1.2% | 3,376,042 | Added+250,000 | |
| Celcuity Inc | NOTE 0.250% 8/0 | 15102KAB6 | 114 | 1.2% | $100,000,000 principal | New+100,000,000 | |
| Arrowhead Pharmaceuticals inARWR | COM | 04280A100 | 113 | 1.2% | 1,389,055 | Reduced−184,242 | |
| Dianthus Therapeutics IncDNTH | COM | 252828108 | 110 | 1.1% | 1,125,313 | Added+105,500 | |
| Larimar Therapeutics IncLRMR | COM | 517125100 | 109 | 1.1% | 35,606,974 | Unchanged | |
| Mineralys Therapeutics IncMLYS | COM | 603170101 | 107 | 1.1% | 3,958,000 | New+3,958,000 | |
| Alignment Healthcare Inc | NOTE 4.250%11/1 | 01625VAB0 | 104 | 1.1% | $61,000,000 principal | Unchanged | |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 101 | 1.1% | 2,714,503 | Added+1,184,495 | |
| Xenon Pharmaceuticals IncXENE | COM | 98420N105 | 97.5 | 1.0% | 1,615,696 | Unchanged | |
| Ionis Pharmaceuticals Inc | NOTE 1.750% 6/1 | 462222AF7 | 93.1 | 1.0% | $60,000,000 principal | Unchanged | |
| Savara IncSVRA | COM | 805111101 | 83.6 | 0.9% | 13,569,000 | Unchanged | |
| Lantheus Holdings IncLNTH | COM | 516544103 | 83.5 | 0.9% | 752,999 | Reduced−75,000 | |
| Syndax Pharmaceuticals IncSNDX | COM | 87164F105 | 82.6 | 0.9% | 3,779,900 | Unchanged | |
| Zenas Biopharma Inc | NOTE 2.500% 4/0 | 98937LAA3 | 80.3 | 0.8% | $67,200,000 principal | Added+2,200,000 | |
| Biomarin Pharmaceutical IncBMRN | COM | 09061G101 | 76.3 | 0.8% | 1,332,836 | Added+481,280 | |
| Pfizer IncPFE | COM | 717081103 | 73.2 | 0.8% | 3,040,000 | Unchanged | |
| Indivior Pharmaceuticals IncINDV | COM | 45579U109 | 67.7 | 0.7% | 1,648,895 | Reduced−1,448,895 | |
| Bio Rad Labs IncBIO | CL A | 090572207 | 66.4 | 0.7% | 226,070 | Unchanged | |
| ARS Pharmaceuticals IncSPRY | COM | 82835W108 | 60.1 | 0.6% | 7,503,812 | Unchanged | |
| Stoke Therapeutics IncSTOK | COM | 86150R107 | 59.7 | 0.6% | 1,823,500 | Unchanged | |
| Structure Therapeutics IncGPCR | SPONSORED ADS | 86366E106 | 58.3 | 0.6% | 1,086,000 | Added+318,007 | |
| Envista Holdings CorporationNVST | COM | 29415F104 | 58.2 | 0.6% | 2,210,100 | Unchanged | |
| Inspire Med Sys IncINSP | COM | 457730109 | 57.9 | 0.6% | 1,296,862 | Reduced−1,406,376 | |
| Caredx IncCDNA | COM | 14167L103 | 56.9 | 0.6% | 1,997,618 | Reduced−193,382 | |
| Boston Scientific CorpBSX | COM | 101137107 | 56.1 | 0.6% | 1,315,000 | New+1,315,000 | |
| Belite Bio IncBLTE | SPONSORED ADS | 07782B104 | 55.0 | 0.6% | 357,199 | Added+53,186 | |
| Parabilis Medicines IncPBLS | COM | 698955101 | 51.5 | 0.5% | 1,880,704 | New+1,880,704 | |
| Certara IncCERT | COM | 15687V109 | 49.2 | 0.5% | 7,512,928 | Reduced−295,677 | |
| Disc Medicine IncIRON | COM | 254604101 | 48.1 | 0.5% | 657,000 | Unchanged | |
| Livanova plc | NOTE 2.500% 3/1 | 53802LAB8 | 46.5 | 0.5% | $34,280,000 principal | Unchanged | |
| Bridgebio Oncology TherapeutBBOT | COM NEW | 107924102 | 37.2 | 0.4% | 4,885,446 | Unchanged | |
| Tyra Biosciences IncTYRA | COM | 90240B106 | 32.5 | 0.3% | 1,017,000 | Added+468,000 | |
| Monopar Therapeutics IncMNPR | COM NEW | 61023L207 | 30.0 | 0.3% | 323,745 | Unchanged | |
| Sionna Therapeutics IncSION | COM | 829401108 | 30.0 | 0.3% | 680,916 | Reduced−289,674 | |
| Immunocore Holdings plc | NOTE 2.500% 2/0 | 45258DAB1 | 27.1 | 0.3% | $30,000,000 principal | Unchanged | |
| Avalyn Pharmaceuticals IncAVLN | COM SHS | 05348Y105 | 24.1 | 0.3% | 731,000 | New+731,000 | |
| Foghorn Therapeutics IncFHTX | COM | 344174107 | 21.4 | 0.2% | 4,394,367 | Unchanged | |
| Beta Bionics IncBBNX | COM | 08659B102 | 20.7 | 0.2% | 1,324,000 | Unchanged | |
| Alnylam Pharmaceuticals IncALNY | COM | 02043Q107 | 20.5 | 0.2% | 67,935 | Unchanged | |
| Bright Minds Biosciences IncDRUG | COM NEW | 10919W405 | 19.9 | 0.2% | 283,000 | Unchanged | |
| Odyssey Therapeutics IncODTX | COMMON STOCK | 67613T104 | 19.6 | 0.2% | 1,046,139 | New+1,046,139 | |
| The Oncology Institute IncSTLN | COM | 68236X100 | 18.2 | 0.2% | 3,360,052 | Unchanged | |
| Kyverna Therapeutics IncKYTX | COM | 501976104 | 17.8 | 0.2% | 2,000,000 | Unchanged | |
| Alamar Biosciences IncALMR | COMMON STOCK | 010911105 | 16.3 | 0.2% | 600,000 | New+600,000 | |
| Chemed Corp NewCHE | COM | 16359R103 | 14.0 | 0.1% | 30,000 | New+30,000 | |
| Spyglass Pharma IncSGP | COM SHS | 85220G109 | 12.2 | 0.1% | 550,000 | Unchanged | |
| Neogenomics Inc | NOTE 0.250% 1/1 | 64049MAB6 | 12.2 | 0.1% | $13,040,000 principal | Reduced−59,649,000 | |
| Adagene IncADAG | ADS | 005329107 | 11.2 | 0.1% | 2,666,666 | New+2,666,666 | |
| Hemab Therapeutics Holdings IncCOAG | COM SHS | 423494103 | 10.1 | 0.1% | 275,000 | New+275,000 | |
| Mobia Med IncMOBI | COMMON STOCK | 60705V103 | 9.0 | <0.1% | 670,752 | New+670,752 | |
| Embecta CorpEMBC | COMMON STOCK | 29082K105 | 8.3 | <0.1% | 2,534,961 | Unchanged | |
| Veracyte IncVCYT | COM | 92337F107 | 5.9 | <0.1% | 101,000 | Reduced−625,000 | |
| Annexon IncANNX | COM | 03589W102 | 3.3 | <0.1% | 583,913 | Unchanged | |
| Alector IncALEC | COM | 014442107 | 2.1 | <0.1% | 1,055,192 | Unchanged | |
| Newamsterdam Pharma Company | *W EXP 99/99/999 | N62509117 | 2.0 | <0.1% | 92,787 | Unchanged | |
| Edwards Lifesciences CorpEW | COM | 28176E108 | 1.2 | <0.1% | 13,702 | Unchanged | |
| Mirum Pharmaceuticals IncMIRM | COM | 604749101 | 0.7 | <0.1% | 6,027 | New+6,027 | |
| Humana IncHUM | COM | 444859102 | 0.4 | <0.1% | 917 | Unchanged | |
| The Oncology Institute IncSTLN | *W EXP 99/99/999 | 68236X118 | 0.1 | <0.1% | 1,250,000 | Unchanged | |
| PMV Pharmaceuticals IncPMVP | COM | 69353Y103 | 0.0 | <0.1% | 8,790 | Unchanged | |
| Surrozen Inc | *W EXP 08/01/203 | 86889P117 | 0.0 | <0.1% | 166,666 | Unchanged |
Sold out: 13 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Biomx Inc | COM NEW | 09090D509 | 0.0 | 0.0% | 0 | Sold out−131,272 | |
| Catalyst Pharmaceuticals Inc | COM | 14888U101 | 0.0 | 0.0% | 0 | Sold out−3,943,600 | |
| Compass Therapeutics IncCMPX | COM | 20454B104 | 0.0 | 0.0% | 0 | Sold out−3,606,000 | |
| Cullinan Therapeutics IncCGEM | COM | 230031106 | 0.0 | 0.0% | 0 | Sold out−386,169 | |
| DAY One Biopharmaceuticals I | COM | 23954D109 | 0.0 | 0.0% | 0 | Sold out−3,723,131 | |
| Enhabit Inc | COM | 29332G102 | 0.0 | 0.0% | 0 | Sold out−4,747,746 | |
| Kymera Therapeutics IncKYMR | COM | 501575104 | 0.0 | 0.0% | 0 | Sold out−561,170 | |
| Mirum Pharmaceuticals Inc | NOTE 4.000% 5/0 | 604749AB7 | 0.0 | 0.0% | $0 principal | Sold out−70,000,000 | |
| Myriad Genetics IncMYGN | COM | 62855J104 | 0.0 | 0.0% | 0 | Sold out−505 | |
| Neurocrine Biosciences IncNBIX | COM | 64125C109 | 0.0 | 0.0% | 0 | Sold out−610,000 | |
| Quantum Si Inc | *W EXP 06/10/202 | 74765K113 | 0.0 | 0.0% | 0 | Sold out−333,333 | |
| Taysha Gene Therapies IncTSHA | COM SHS | 877619106 | 0.0 | 0.0% | 0 | Sold out−2,722,165 | |
| Veradermics IncMANE | COMMON STOCK | 922967104 | 0.0 | 0.0% | 0 | Sold out−5,000 |
Source: SEC EDGAR, Form 13F-HR, accession 0001213900-26-089991 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.